Businesses are finding that AI is a great leveller. Organisations with mature digital infrastructures can use AI to unlock ...

As an oncologist with more than 25 years of experience across clinical care, research, drug and device development, and ...

Theramex, a London, UK-based specialty pharma company focusing on women's health, is changing hands in a deal reportedly ...

Novo has raised its financial guidance for 2026 on the back of rising sales of its oral weight-loss therapy Wegovy, which ...

Boehringer Ingelheim is paying $358 million upfront to claim options on up to six antibody-drug conjugates (ADCs) and T cell engagers (TCEs) developed by China's Sino Biopharma (SBP Group), extending ...

The BioInnovation Institute (BII) has expanded a network striving to develop treatments for cardiometabolic diseases and ...

Hard on the heels of a £1 billion investment package by pharma companies in last week's UK Budget, AbbVie has pledged another ...

Bayer's pharma unit has reached a "turning point" in its growth trajectory as sales of new medicines rose 6.4% in the third ...

The WuXi agreement gives Fresenius "full strategic flexibility" to choose which biosimilar candidates to develop and gives ...

Dojolvi was approved in the US in 2020 and was also launched in Japan earlier this year. Ultragenyx recorded sales of $45 ...

Hutchmed and AstraZeneca's Orpathys is now under review in Europe and Japan for MET-driven, EGFR-mutated lung cancer, a few ...

Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid) has been granted an accelerated approval by the FDA as a ...